NEW YORK (360Dx) – Siemens Healthineers has announced the commercial launch of a CE-marked immunoassay for Zika virus detection — the Novagnost Zika Virus IgM µ-capture Assay.

The firm said that the immunoassay enables enhanced patient outcomes through differential diagnostics in line with a World Health Organization test algorithm, and that the assay is available for sale in countries outside the US that accept the CE mark.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.